NCT03938922撤回1 期
A Multicenter, Open Label Study to Evaluate Tolerability and Efficacy of Orally Administered ENT-01 for the Treatment of Parkinson's Disease Dementia.
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 撤回
- 发起方
- Enterin Inc.
- 试验地点
- 3
- 主要终点
- Cognition Improvement by Dementia Severity Rating Scale (DSRS) - Primary Outcome
研究概览
简要总结
This study will be conducted as a multi-center, open label study in the US. There will be 40 patient to receive the active investigational product.
详细描述
The study will be conducted on an out-patient basis. Each patient will have 5 visits to the clinic: a screening visit, a randomization visit, 1 followup visit, 1 end of treatment visit, and 1 end of study visit.
Patients will be allowed to adjust their dosing, based upon protocol specifications. Rescue medications will be provided to all patients to ensure they move their bowels on a regular basis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 30 Years 至 90 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients aged 30-90 years, both genders
- •Patients or care-giver must provide informed consent and be willing and able to comply with study procedures.
- •Patients must be diagnosed with Parkinson's disease defined as the presence of at least three of the following cardinal features, in the absence of alternative explanations or atypical features: rest tremor, rigidity, bradykinesia and/or akinesia, postural and gait abnormalities.
- •Patients must have dementia as defined by (1) decline in cognitive function and (2) functional impairment, which together in, in the opinion of the investigator, has resulted in a clinical diagnosis of dementia.
- •MoCA < 24 in support of a dementia diagnosis
- •Have a reliable and actively involved caregiver who must be able to communicate in English and be willing to comply with protocol requirements.
- •If on anti-parkinsonian agents, participants must be on stable dosage for at least 4 weeks prior to baseline.
- •If on medications enhancing cognition (rivastigmine, galantamine, donepezil, memantine), participants must be on stable dosage for at least 8 weeks prior to baseline.
- •If on antidepressant medications, participants must be on stable dosage for at least 4 weeks prior to baseline.
- •If on clozapine, pimavanserin or quetiapine to address drug-induced or disease-related psychosis, participants must be on stable dosage for 4 weeks prior to baseline.
- •Female patients of childbearing potential must have negative serum or urine pregnancy tests and must not be lactating. For females able to bear children, a hormonal (i.e., oral, implantable, or injectable) and single-barrier method, or a double-barrier method of birth control must be used throughout the study. A vasectomized partner will be allowed as one in conjunction with another single-barrier method.
- •Female patients unable to bear children must have this documented in the case report form (CRF) (i.e., tubal ligation, hysterectomy, or postmenopausal [defined as a minimum of one year since the last menstrual period]). Post-menopausal status will be confirmed by follicle stimulating hormone (FSH) in women less than 60 years of age.
排除标准
- •Patient or caregiver unable or unwilling to provide informed consent or to comply with study procedures.
- •Unable to withdraw proton pump inhibitors at the end of run-in period.
- •Unable to withdraw from anti-cholinergics at the beginning of the run-in period
- •Any clinically significant abnormalities on screening laboratories or physical examination requiring further evaluation or treatment.
- •Neurological disorder other than Parkinson's disease that in the opinion of the investigator might interfere with the conduct of the study
- •Females who are pregnant or breastfeeding
- •History of excessive alcohol use or substance abuse
- •Psychotic disorder was present before the diagnosis of Parkinson's disease
- •Patient or caregiver unable to administer daily oral dosing of study drug
- •Caregiver unwilling or unable to unable to complete stool diary, dispense study medication and accompany the patient to all visits
- •Participation in an investigational drug trial within the month prior to dosing in the present study.
- •A compromised gastrointestinal system which includes: Structural, metabolic, or functional GI diseases or disorders; History of major GI surgery within 30 days (a history of cholecystectomy, polypectomy, hernia repair, appendicectomy, gastric surgery for peptic ulcer and gastric banding for obesity are not exclusionary as long as they were performed more than 30 days before the screening visit. Partial or complete colectomy is exclusionary).
- •Review of Screening period diaries indicates either of the following: Fewer than 11 days of diary completion; More than 5 complete spontaneous bowel movements per week based upon the average Complete Spontaneous Bowel Movement (CSBM) rate reported during the Screening Period.
- •Any other reason, which in the opinion of the investigator would confound proper interpretation of the study.
研究组 & 干预措施
Active Treatment
Experimental
ENT-01 tablet will be taken once daily by mouth.
干预措施: Active Investigational Treatment ENT-01 (Drug)
结局指标
主要结局
Cognition Improvement by Dementia Severity Rating Scale (DSRS) - Primary Outcome
时间窗: 10 weeks
To determine the safety and efficacy of repeated oral doses of ENT-01 in improving cognition in patients with Parkinson's disease dementia, measured by the Dementia Severity Rating Scale (DSRS). The DSRS Test is used to track changes in cognitive status over time. Its five subscales provide additional information on specific abilities: Attention, Initiation/Perseveration, Construction, Conceptualization, and Memory. The score ranges from 0 to 54, with 0-18 being mild, 19-36 being moderate and 37-54 being severe. Improvements would be indicated by lower scores from baseline to end of fixed dose period.
次要结局
- Change from Baseline in Montreal Cognitive Assessment (MOCA) - Secondary Outcomes(10 weeks)
- Change from Baseline to the End of the Fixed Dose Period in Symptoms Adapted for Parkinson's Disease (SAPS-PD) - Secondary Outcomes(10 weeks)
- Change from Baseline to the End of the Fixed Dose Period in Neuropsychiatric Inventory (NPI) and Caregiver Distress (NPI-D) - Secondary Outcomes(10 weeks)
- Change from Baseline to the End of the Fixed Dose Period in Parkinson's Disease Questionnaire-39 (PDQ-39) - Secondary Outcomes(10 weeks)
研究者
研究点 (3)
Loading locations...
相似试验
已完成
3 期
Evaluation of Two Glatiramer Acetate (GA) Formulations in Relapsing-Remitting Multiple Sclerosis (RRMS) PatientsMultiple SclerosisNCT01167426Teva Neuroscience, Inc.148
已完成
3 期
Study to Evaluate the Long-Term Safety of PA32540 in Subjects Who Are at Risk for Developing Aspirin-Associated Gastric UlcersAspirin-Associated Gastric UlcersNCT00995410POZEN380
招募中
2 期
Long-term Safety and Tolerability of HSK39297 in Patients With Paroxysmal Nocturnal HemoglobinuriaParoxysmal Nocturnal HemoglobinuriaNCT06745622Haisco Pharmaceutical Group Co., Ltd.47
终止
3 期
A Study to Evaluate the Safety, Tolerability, and Efficacy of Long-Term Gantenerumab Administration in Participants With Alzheimer's Disease (AD)Alzheimer DiseaseNCT04374253Hoffmann-La Roche1,382
已完成
3 期
Safety and Tolerability of Glatiramer AcetateRelapsing-Remitting Multiple SclerosisNCT01874145Teva Branded Pharmaceutical Products R&D, Inc.209